Wake Forest University
wfu.eduMatched: Wake Forest University Health Sciences · Wake Forest University
Live pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,452
Active
260
Phase 3
45
Total enrollment
892,277
Pipeline matrix
Showing 40 of 116 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Duloxetine 30 MG | — | — | — | — | — | 2 | |
| Liposomal bupivacaine | — | — | — | 7 | |||
| Normal Saline | — | — | 4 | ||||
| Triamcinolone Acetonide | — | — | — | — | — | 2 | |
| Ruxolitinib | — | — | — | — | 2 | ||
| Oxycodone | — | — | — | — | 2 | ||
| Angiotensin II | — | — | — | — | — | 2 | |
| Antibiotic coated intramedullary Nail | — | — | — | — | — | 1 | |
| Estradiol vaginal cream | — | — | — | — | — | 1 | |
| Estradiol Vaginal | — | — | — | — | — | 1 | |
| levetiracetam | — | — | — | — | — | 1 | |
| lacosamide | — | — | — | — | — | 1 | |
| Phentermine Hydrochloride 8 MG | — | — | — | — | — | 1 | |
| Azithromycin Prophylaxis | — | — | — | — | — | 1 | |
| Azithromycin Placebo | — | — | — | — | — | 1 | |
| Cefazolin | — | — | — | — | — | 1 | |
| Fluoxetine 20 MG | — | — | — | — | — | 1 | |
| ruxolitinib and an Eczema Action Plan | — | — | — | — | — | 1 | |
| Antibiotic | — | — | — | — | — | 1 | |
| Buprenorphine | — | — | — | — | — | 1 | |
| Bupivacaine, Clonidine, Epinephrine, Buprenorphine and Dexamethasone (BPV-CEBD) Combination | — | — | — | — | — | 1 | |
| Bisphosphonate | — | — | — | — | — | 1 | |
| Xeomin® | — | — | — | — | — | 1 | |
| Norepinephrine | — | — | — | — | — | 1 | |
| Topical steroid class I-II | — | — | — | — | — | 1 | |
| Doxycyline | — | — | — | — | — | 1 | |
| Minoxidil | — | — | — | — | — | 1 | |
| Exparel/bupivacaine mixture | — | — | — | — | — | 1 | |
| Tirzepatide | — | — | — | — | — | 1 | |
| Fisetin followed by Placebo | — | — | — | — | — | 1 | |
| Single dose of methadone | — | — | — | — | — | 1 | |
| Split dose of methadone | — | — | — | — | — | 1 | |
| Balanced split dose of methadone | — | — | — | — | — | 1 | |
| Nicardipine | — | — | — | — | — | 1 | |
| Saline | — | 7 | |||||
| Epinephrine | — | — | — | — | 3 | ||
| Exparel | — | — | — | — | 2 | ||
| risedronate | — | — | — | — | 2 | ||
| Betamethasone dipropionate 0.05% | — | — | — | — | — | 1 | |
| Tapinarof | — | — | — | — | — | 1 |
76 more active programs hidden
Next readouts
- 2022-09-01
- 2023-06-28
- 2023-07-12
- 2024-03-28
- 2025-06-19
- 2026-03-21
- 2026-06-30
- 2026-07
- 2026-08
- 2026-09
Top conditions
- Obesity41
- Breast Cancer38
- Pain27
- Depression27
- Cancer23
- Anxiety22
- Lung Cancer21
- Head and Neck Cancer20
Frequently asked questions about Wake Forest University
- How many clinical trials does Wake Forest University have on ClinicalTrials.gov?
- Wake Forest University is listed as the lead sponsor on 1,452 clinical trials in ClinicalTrials.gov, 260 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Wake Forest University's trials are in Phase 3?
- 45 of Wake Forest University's trials are in Phase 3, spread across 116 active drug programs.
- What therapeutic areas does Wake Forest University focus on?
- Wake Forest University's most-studied conditions on ClinicalTrials.gov are Obesity, Breast Cancer, Pain, Depression, Cancer.
- When are Wake Forest University's next clinical trial readouts?
- Wake Forest University has 10 upcoming primary-completion readouts tracked here; the soonest is “A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer”, expected around 2022-09-01.